Novartis has announced plans to invest $23 billion over 5 years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S. patients will be made in the United States. This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional U.S. jobs. The production capacity will cover both active...